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Background: Relapses of childhood steroid-sensitive nephrotic syndrome (SSNS) are treated with a 4- to 8-week
course of high-dose oral prednisolone, which may be associated with significant adverse effects. There is a clear
association between upper respiratory tract infection (URTI) and relapse development. Previous studies in developing
nations have suggested that introducing a 5- to 7-day course of daily prednisolone during an URTI may prevent a
relapse developing and the need for a treatment course of high-dose prednisolone. The aim of PREDNOS 2 is to
evaluate the effectiveness of a 6-day course of daily prednisolone therapy during an URTI in reducing the development
of a subsequent relapse in a developed nation.
Methods/design: The subjects will be 300 children with relapsing SSNS (≥2 relapses in preceding year), who will be
randomised to receive either a 6-day course of daily prednisolone or no change to their current therapy (with the use
of placebo to double blind) each time they develop an URTI over 12 months. A strict definition for URTI will be used.
Subjects will be reviewed at 3, 6, 9 and 12 months to capture data regarding relapse history, ongoing therapy and
adverse effect profile, including behavioural problems and quality of life. A formal health economic analysis will also
be performed. The primary end point of the study will be the incidence of URTI-related relapse (3 days of Albustix +++)
following the first infection during the 12-month follow-up period. DNA and RNA samples will be collected to identify
a potential genetic cause for the disease. Subjects will be recruited from over 100 UK centres with the assistance of
the Medicines for Children Research Network.
PREDNOS 2 is funded by the National Institute for Health Research Health Technology Assessment Programme
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Discussion: We propose that PREDNOS 2 will be a pivotal study that will inform the future standard of care for
children with SSNS. If it is possible to reduce the disease relapse rate effectively and safely, this will reduce the
morbidity and cost associated with drug treatment, notwithstanding hospital admission and parental absence from
employment.
Trial registration: Current Controlled Trials (ISRCTN10900733).
Keywords: Steroid sensitive nephrotic syndrome, Relapse, Upper respiratory tract infection, Prednisolone, Adverse
effects, Health economic analysisBackground
Idiopathic nephrotic syndrome is the commonest glom-
erular disease of childhood, with an incidence of 2 cases
per 100,000 children in the UK [1]. The presenting
episode is treated with high-dose oral prednisolone to
which >90% make a complete response, responders re-
ceiving the diagnostic label of steroid-sensitive nephrotic
syndrome (SSNS) [2,3]. The optimum duration of pred-
nisolone therapy at presentation remains unclear and is
currently being further investigated in the PREDNOS
study (ISRCTN16645249).
Following successful initial treatment, 70% to 80% of
children develop disease relapses necessitating further
4- to 8-week courses of high-dose prednisolone, and
around 50% develop frequently relapsing disease [4].
Various long-term immunosuppressive strategies are
employed to reduce the frequency of relapses in those
with frequently relapsing disease. These include long-
term low-dose alternate-day prednisolone, levamisole,
cyclophosphamide, ciclosporin, tacrolimus, mycopheno-
late mofetil and rituximab.
Nephrotic syndrome relapses are associated with a risk
of significant complications, including sepsis, throm-
bosis, dyslipidaemia and malnutrition [5]. The treatment
of relapses with high-dose prednisolone is associated
with major adverse effects, including hip avascular ne-
crosis, hypertension, diabetes and behavioural problems
[6]. Furthermore, children miss school during relapses,
resulting in impaired academic performance and paren-
tal absence from work. It is well recognised that at least
50% of relapses are precipitated by a viral upper respira-
tory tract infection (URTI), possibly mediated through
cytokine release [7]. Given this causal association, and
the morbidity and cost associated with relapse and its
treatment, it is logical that attempts are made to ameli-
orate the URTI-driven process.
Three studies published to date suggest that in chil-
dren from Middle Eastern and Asian countries (Saudi
Arabia, Sri Lanka and India) with relapsing SSNS receiv-
ing long-term alternate-day prednisolone therapy, the
use of a 5- to 7-day course of daily prednisolone therapy
(i.e. switching from alternate day to daily dosing) at the
time of development of intercurrent URTI associatedwith fever is associated with a lower rate of subsequent
relapse of nephrotic syndrome than when no such
change is made to their therapy (current standard care)
[8-10]. There were, however, a number of methodo-
logical issues with some of these studies, and the strictly
defined patient populations under investigation limit the
applicability of the study findings to children with SSNS
in developed nations, where the pattern of childhood
URTI is significantly different, with lower incidence of
fever and general absence of diarrhoea. Furthermore,
these previous studies have been restricted to children
receiving low- to medium-dose long-term maintenance
prednisolone (plus levamisole in the Indian study [10])
and it is currently not clear whether intervention with a
short course of daily prednisolone at the time of URTI is
effective in children receiving other immunomodulatory
therapies, e.g. levamisole, ciclosporin, tacrolimus and myco-
phenolate mofetil, either alone, or in conjunction with
long-term maintenance prednisolone. The adverse effects
of prednisolone, including its effect on behaviour, were not
comprehensively assessed, nor were quality of life or the
cost-effectiveness of the intervention. The PREDNOS 2
study will provide important definitive evidence to assess
the effectiveness of a 6-day course of daily prednisolone
therapy at the time of development of URTI in reducing
the development of subsequent nephrotic syndrome relapse
in children with relapsing SSNS in a developed nation.
Methods/design
A flow chart for the study is shown in Figure 1.
Aim
The aim of the study is to assess the effectiveness of a
6-day course of daily prednisolone therapy at the time
of onset of URTI in reducing the development of subse-
quent nephrotic syndrome relapse in children with
relapsing SSNS.
Study design
PREDNOS 2 will be conducted as a phase III rando-
mised parallel-group placebo-controlled double-blind
trial, comparing a 6-day course of daily prednisolone
with no change in therapy using a matching placebo.
Child with relapsing steroid sensitive
nephrotic syndrome
 (≥2 relapses in  preceding 12 months)
Randomised (post-recruitment)
Active treatment arm
Prednisolone administered daily for
6 days commenced within 24 hours
of onset of first URTI
Prednisolone administered daily 
for 6 days commenced within 24 
hours of onset of each
subsequent URTI over 12 month 
follow-up period
Control arm
No change to current prednisolone 
at time of first URTI with
 use of placebo tablets to blind study
No change to current prednisolone 
at time of each subsequent URTI
over 12 month follow-up period
with use of placebo tablets 
to blind study
Figure 1 Trial schema.
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for study set-up, 2 years of recruitment, 1 year of follow-
up and 6 months for data analysis.
Recruitment
Children with relapsing SSNS under the care of a paedi-
atric nephrologist and/or a general paediatrician will be
recruited from over 100 centres throughout the UK.
Potential subjects will be identified from clinic lists and
departmental databases. Information sheets outlining
the study will be mailed to the parents or guardians of
potentially eligible children (and the child where age
appropriate), 1 to 2 weeks prior to their next clinical
appointment. Following confirmation of eligibility with
regard to inclusion and exclusion criteria (see below)and a further full discussion of the study, informed con-
sent will then be sought from the parents (or guardians)
and subjects (informed consent or assent according to
age) at the time of this review.
Inclusion and exclusion criteria
Inclusion criteria:
 Diagnosis of relapsing SSNS with two or more
relapses in the 12 months prior to enrolment
 Age 2 to 19 years inclusive
 Parents/guardians and subject (where age appropriate)
understand the definition of URTI and the need
to commence the study drug once this definition
has been met
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subject’s parents/guardians and written assent
obtained from subject (where age appropriate).
Subjects aged 16 years and above will provide
their own written informed consent
 Subjects who have previously received a course
of oral or intravenous cyclophosphamide:
○ Must have experienced two relapses in the
12 months prior to randomisation (in keeping
with all other subjects)
○ Must have experienced at least one of
these relapses following completion of
cyclophosphamide therapy
○ Must be at least 3 months post completion of
oral or intravenous cyclophosphamide therapy
 Subjects who have previously received a single dose
or course of intravenous rituximab:
○ Must have experienced two relapses in the
12 months prior to randomisation (in keeping
with all other subjects)
○ Must have experienced at least one of these
relapses following completion of rituximab
therapy
○ Must be at least 3 months post completion of
intravenous rituximab therapy
Subjects with a diagnosis of relapsing SSNS will
include:
 Subjects not on long-term immunomodulatory
therapy
 Subjects receiving long-term maintenance prednisolone
therapy at a dose of up to and including 15 mg/m2 on
alternate days
 Subjects receiving long-term maintenance prednisolone
therapy at a dose of up to and including 15 mg/m2 on
alternate days in conjunction with other immunomod-
ulatory therapies, including levamisole, ciclosporin,
tacrolimus, mycophenolate mofetil, mycophenolate
sodium and azathioprine
 Subjects receiving long-term immunomodulatory
therapies, including levamisole, ciclosporin, tacrolimus,
mycophenolate mofetil, mycophenolate sodium
and azathioprine without long-term maintenance
prednisolone therapy
Exclusion criteria:
 Steroid-resistant nephrotic syndrome
 Receiving or within 3 months of completion of a
course of oral or intravenous cyclophosphamide
 Receiving or within 3 months of completion of a
course of rituximab
 Daily prednisolone therapy Subjects on a prednisolone dose of greater than
15 mg/m2 on alternate days
 Documented history of significant non-adherence
with medical therapy
 Planned transfer from paediatric to adult services
during the 12-month study period
 Inability to take prednisolone tablets, even in
crushed form
 Known allergy to prednisolone
Daily prednisolone therapy or alternate-day prednisol-
one therapy refers to a dose of prednisolone at the time
of randomisation only. If the prednisolone dose increases
during the 12-month study period, e.g. after a relapse,
the subject may remain in the study.
Randomisation and allocation concealment
Following the completion of the baseline assessments,
subjects will be randomised at the level of the individual
on a 1:1 basis to either the active treatment or control
arm. Randomisation will be provided by a computer-
generated programme at the University of Birmingham
Clinical Trials Unit (BCTU). The randomisation will
be stratified by the treatment regimen that the subject
is receiving at randomisation (no treatment, long-term
maintenance prednisolone therapy only, long-term main-
tenance prednisolone therapy with other immunosuppres-
sant therapy and other immunosuppressant therapy only).
Treatment allocation will only be revealed to the central
pharmacy dispensing the study drug at Birmingham Chil-
dren’s Hospital.
The study drug (prednisolone 5 mg tablets and match-
ing placebo) will be manufactured, packed and labelled
by Essential Nutrition. Following randomisation, subjects
will be provided with a supply of 100 tablets (two con-
tainers of 50 tablets) of the study drug (prednisolone
5 mg for those randomised to the active treatment arm
or a matching placebo for those randomised to the con-
trol arm). This will be sent directly to the family home
from the central pharmacy at the Birmingham Children’s
Hospital by Royal Mail registered post on a day conveni-
ent for the family. The study drug containers and their
contents will appear identical in every way, thus main-
taining the double blind. Study drug labelling will comply
with the applicable regulatory requirements and clinical
trial specific labels will be attached to all treatments.
Birmingham Children’s Hospital Pharmacy will maintain
drug accountability logs for dispensed and returned study
drug doses according to their local policy.
Planned interventions
Current clinical practice is for no change to be made to
immunomodulatory therapy at the time of development
of an URTI. The intervention being assessed within
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therapy at the time of onset of URTI. Those randomised
to the active treatment arm will commence a 6-day
course of daily prednisolone each time they develop an
URTI (see below for definition) during the 12 months of
the trial. Those randomised to the control arm will
receive an identical number of placebo tablets, thus
allowing double blinding of the study. If the subject is
receiving background long-term immunomodulatory
therapy (e.g. levamisole or ciclosporin), then this will
continue unchanged (see below for examples).
Definition of an upper respiratory tract infection
An URTI will be defined by the presence of at least two
of the following for at least 24 hours:
 Sore throat
 Ear pain or discharge
 Runny nose
 Cough (dry or barking)
 Hoarse voice
 Fever >37°C (measured using a tympanometric
electronic thermometer)
Parents or guardians will be provided with clear written
and (if requested) downloadable electronic information re-
garding the study definition of an URTI as outlined above.
They will also be provided with an abbreviated version
printed onto laminated cards and in a fridge magnet
format. An electronic tympanometric thermometer will
be provided to facilitate measurement of their child’s
temperature, as well as a study diary to record the re-
sults of the daily morning urinalysis (standard care in
children with relapsing SSNS to allow the early identifi-
cation of disease relapse), development of URTI, com-
mencement of study drug, other ongoing treatment,
acute illnesses and any other issues they feel might be
important for the trial.
Commencement of study drug
Once the subject meets the definition for URTI (two or
more criteria as listed above for at least 24 hours), the
parents or guardians will commence the subject on the
study drug (prednisolone tablets for those in the active
treatment arm or placebo for those in the control arm;
see below for dosing schedules). It is anticipated that
parents or guardians will have no difficulties in identify-
ing that their child has met the URTI criteria and will
commence the study drug unassisted, having been pro-
vided with comprehensive advice on this at the time of
their recruitment. However, a back-up service will also
be in place: if they are in any doubt, parents or guardians
will be instructed to contact their local study site, or
if this is not possible, to call a PREDNOS 2 studytelephone number. This will be manned by the chief
investigator or his nominated deputy during periods of
annual leave. Through this service, parents or guardians
will be able to seek advice regarding whether their child
meets the URTI criteria, the dose of study drug required,
and any other issues or concerns they may have relating
to the study. A log of these telephone calls will be main-
tained, and the chief investigator will report their con-
tent to the local principal investigator by email.
To ensure patient safety, the information provided to
parents and guardians will also contain information
about the signs of a more serious infection (non-
blanching rash, leg pain, cool extremities, rapid breath-
ing, blue lips, fitting, unconsciousness or any other
major concern). If any of these features are present, par-
ents and guardians will be instructed not to start the
study drug and to seek urgent medical attention for their
child from their general practitioner or local accident
and emergency department. Parents or guardians will be
asked to contact their local study site within 24 hours of
commencing the study drug to inform the principal in-
vestigator or nominated deputy and to allow them the
opportunity to discuss any of their child’s symptoms that
may be of concern to them.
Further commencement of study drug
The above intervention will be repeated every time the
child develops an URTI over the 12-month follow-up
period. The only exception to this is if the child is
receiving daily prednisolone therapy, e.g. in the early
stages of treatment for a previous relapse – in this in-
stance the study drug will not be commenced.
Dosing of study drug
The precise dose of the study drug at time of the devel-
opment of URTI will depend upon the subject’s current
treatment regimen, in particular whether they are receiv-
ing long-term maintenance prednisolone therapy and if
so, at what dose.
Subjects not receiving long-term maintenance prednisolone
Those randomised to the active treatment arm will
receive prednisolone 15 mg/m2 daily (maximum dose
40 mg) for a total of 6 days. The dose will be rounded
up or down to the nearest 5 mg and given as a single
morning dose. Subjects randomised to the control arm
will receive an identical number of placebo tablets.
Subjects receiving a long-term maintenance prednisolone
dose of ≤15 mg/m2 on alternate days
Those randomised to the active treatment arm will
receive prednisolone 15 mg/m2 daily (maximum dose
40 mg) for a total of 6 days. The dose will be rounded
up or down to the nearest 5 mg and given as a single
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will receive an identical number of placebo tablets.
These subjects receiving long-term maintenance pred-
nisolone therapy will receive a different number of
tablets of the study drug on regular treatment days
(i.e. those days when they usually take prednisolone)
from non-treatment days. For example, a child of 1.0 m2
receiving a long-term maintenance dose of 5 mg of
prednisolone on alternate days will take an additional
2 × 5 mg prednisolone tablets (or matching placebo) on
treatment days and 3 × 5 mg prednisolone tablets (or
matching placebo) on non-treatment days. This particu-
lar subject would therefore either receive prednisolone
15 mg (15 mg/m2) daily for 6 days if in the active treat-
ment arm or continue unchanged on prednisolone 5 mg
on alternate days if in the control arm.
Subjects receiving a prednisolone dose of >15 mg/m2
A small number of subjects will be receiving a prednisol-
one dose of >15 mg/m2 at the time of URTI development.
They will have already relapsed during the 12-month
study period and had their prednisolone dose increased
accordingly as the inclusion/exclusion criteria exclude
those on a dose of prednisolone >15 mg/m2 at study entry.
These subjects will convert to the same dose on a daily
basis for a total of 6 days. The dose will be rounded up or
down to the nearest 5 mg and given as a single morning
dose (maximum dose 60 mg). Subjects randomised to the
control arm will receive an identical number of placebo
tablets. For example, a child of 1.0 m2 receiving a long-
term maintenance dose of 20 mg of prednisolone on alter-
nate days will take their regular dose on treatment days
and 4 × 5 mg prednisolone tablets (or matching placebo)
on non-treatment days. This particular subject would
therefore either receive 20 mg (20 mg/m2) daily for 6 days
if in the active treatment arm or continue unchanged on
20 mg on alternate days if in the control arm.
The study drug dose to be used on development of an
URTI may change during the study due to alterations in
the subject’s long-term maintenance prednisolone dose
and normal childhood growth. The precise regimen to
be administered will be discussed with parents and
guardians along with a written treatment plan at the
time of recruitment and (in light of the above) will be
re-discussed at each study visit. Information about the
precise number of study drug tablets to administer will
be provided to the family in written form, using a stand-
ard form, which will be completed by the local principal
investigator.
The study drug will always be given as a single dose in
the morning. If the subject is receiving an additional im-
munomodulatory therapy, e.g. ciclosporin, levamisole,
etc., this will continue unchanged throughout the 6-day
course of the study drug. Other drug treatment will alsocontinue unchanged. At the end of the 6-day course of
the study drug, the subject will continue on their previ-
ous dose of long-term maintenance prednisolone ther-
apy (or no prednisolone treatment if they were not
previously receiving this). Other drug treatment will
continue unchanged.
When URTI occurs whilst children are receiving daily
prednisolone, e.g. in the early stages of treatment for a
disease relapse, the study drug will not be commenced.
Subjects can continue to participate in the study and the
subsequent URTIs will be treated with the study drug
provided that they are receiving alternate-day prednisol-
one at this point.
Information recorded by parents and guardians
Parents or guardians will perform dipstick testing for
proteinuria (using an Albustix, Siemens Healthcare
Diagnostics Ltd, Frimley, UK) of the subject’s first morn-
ing urine on a daily basis in accordance with routine
clinical care. They will be provided with a subject-held
record book to enter the results (to allow the early
detection of nephrotic syndrome relapses) and the medi-
cation administered on a daily basis. This will be main-
tained for the 12 months of the study. Parents and
guardians will also use this diary to record any intercur-
rent illness and consultations with healthcare profes-
sionals (general practitioner, nurse, hospital accident and
emergency department, etc.), development of URTI, and
commencement of study medicines, along with details of
medicines prescribed or purchased over the counter.
Diagnosis and treatment of relapse
Relapse is defined as Albustix +++ (3+) or more for
three consecutive days or the presence of generalised
oedema and Albustix 3+ on urine testing. An URTI-
related relapse is defined as a relapse occurring within
14 days of the onset of an URTI. Where disease relapse
occurs, parents or guardians will contact their study
centre in accordance with routine clinical care and treat-
ment for disease relapse will be commenced. A relapse
will be treated in accordance with the International
Study of Kidney Disease in Children relapse regimen:
prednisolone will be commenced at a dose of 60 mg/m2
daily (maximum dose 80 mg) until the urine tests are
negative or trace for three consecutive days, then re-
duced to 40 mg/m2 (maximum dose 60 mg) on alternate
days for 4 weeks (14 doses). A subsequent tapering dose
can be used at the individual physician’s discretion.
When relapse therapy is commenced, long-term main-
tenance prednisolone therapy (e.g. 10 mg on alternate
days) is discontinued. Where relapse occurs whilst the
child is receiving the 6-day course of the study drug, this
will also be discontinued. Once the relapse regimen has
been completed, long-term maintenance prednisolone
Webb et al. Trials 2014, 15:147 Page 7 of 12
http://www.trialsjournal.com/content/15/1/147therapy may be recommenced at any dose at the princi-
pal investigator’s discretion. Background immunomodu-
latory therapy other than prednisolone, e.g. ciclosporin,
mycophenolate mofetil, levamisole, etc., will continue
unchanged throughout the relapse treatment period.
Escalation of background immunomodulatory therapy
Subjects will only undergo intensification of background
immunomodulatory therapy (i.e. the addition of, or change
to, a new immunomodulatory agent e.g. ciclosporin, myco-
phenolate mofetil, levamisole, etc.) when there are two or
more relapses of their nephrotic syndrome (URTI-related
or unrelated) in any 6-month period or where there are un-
acceptable adverse effects of prednisolone or other therapy.
These subjects will remain under follow-up: intensification
of immunomodulatory therapy is an important secondary
end point for this study. Similarly, immunomodulatory
therapy will only be discontinued when the subject has
remained relapse-free for at least 6 months or where there
are unacceptable adverse effects of therapy.Table 1 Study visit schedule
Visit
Month
Visit window
Inclusion/exclusion criteria
Informed consent
Randomisation (post-recruitment)
Allocation of study number
Documentation of URTI
Documentation of commencement of study drug
Documentation of recent relapse
Recent medical and drug history
Adverse event documentation
Compliance check (tablet count using counting triangle)
Physical exam
Assessment of steroid toxicity
Height and weight
Blood pressure
Calculation of study drug dose to be administered in event of URTI and expl
provision of documentation of this to parents and guardians – includes revie
weight and body surface area to confirm correct dose
If three or more courses of study drug have been administered since previou
parental understanding of definition of URTI
Blood sample for DNA/RNAa
Achenbach Child Behaviour Checklist
PedsQL questionnaire
CHU-9D and EQ-5D questionnaires
Study drug returned to central pharmacy for accountability
aBlood sample to be collected on one single occasion only.
URTI, upper respiratory tract infection.Trial schema and study visit schedule
All subjects will undergo comprehensive assessment at
the randomisation visit and will then be followed up for
12 months from randomisation, with visits once every
3 months at 3, 6, 9 and 12 months for trial follow-up as-
sessments. The information captured at the randomisa-
tion and subsequent visits are shown in Table 1. At each
visit, there will be a full clinical review of the subject,
and a number of different questionnaires will be admin-
istered. The clinical review will include assessment of
whether the subject has had any URTI or non-URTI re-
lated relapses since the last visit, and a review of the
current treatment regimen. To evaluate changes in sub-
ject behaviour associated with the different prednisolone
regimens, the Achenbach Child Behaviour Checklist will
be used. This is a standardised measure made up of 120
items measuring internalising (withdrawn, somatic com-
plaints, anxiety/depression, thought problems) and exter-
nalising (social problems, attention problems, delinquent
and aggressive) behaviour problems. A total Behavioural1 2 3 4 5
0 3 6 9 12
+/-2 weeks +/-2 weeks +/-2 weeks +/-2 weeks
x
x
x
x
x x x x
x x x x
x x x x x
x x x x x
x x x x
x x x x
x x x x x
x x x x x
x x x x x
x x x x
anation and
w of height,
x x x x x
s visit, confirm x x x x
x x x x x
x x x x x
x x x x x
x x x x x
x
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forms the basis of comparison with age- and gender-
matched normative data. Information relating to quality of
life will also be collected using the Child Health Utility 9D
(CHU-9D), EQ-5D (dependent upon subject age) and
PedsQL questionnaires. The CHU-9D is a newly devel-
oped utility measure designed for children aged 5 to
11 years. The EQ-5D is a validated utility measure rou-
tinely used in adult and adolescent populations. Both the
CHU-9D and the EQ-5D will be used to generate data for
the health economic analyses. The PedsQL questionnaire
is a well-validated approach to measuring health-related
quality of life in healthy children and adolescents and
those with acute and chronic health conditions.
Adverse effects due to prednisolone will be assessed by
studying growth (height, weight and body mass index),
Cushingoid features, hypertrichosis, striae, appetite (all
Likert scale), behaviour (Achenbach Child Behaviour
Checklist), blood pressure and urine dipstick analysis for
glycosuria. The development of significant bacterial, viral
or fungal infections and the use of post-varicella expos-
ure prophylaxis (zoster immune globulin or antiviral
therapy) will also be recorded. Information will also be
collected regarding all episodes of consultation with gen-
eral practitioners or hospital medical teams, including
data on treatments prescribed or purchased. This will be
incorporated into the costs to be measured as part of
the health economic analysis (see below).
A single 10 ml blood sample will be collected on one
occasion for those who provide additional consent for
this. DNA and RNA will be extracted for genetic sub-
studies. A genome-wide association study will be used to
identify possible genetic loci associated with SSNS.
Additionally, a rapid screen using direct Sanger sequen-
cing will identify whether mutations in any of the known
genes cloned to date in connection with childhood
nephrotic syndrome are present. If pathogenic variants
are absent, samples will then be subjected to whole ex-
ome analysis.
Subject retention
This visit schedule is in keeping with the frequency of
routine follow-up of children with relapsing SSNS. As
such, we anticipate high rates of subject retention. In the
PREDNOS study (ISRCTN16645249), which has to date
recruited almost 200 newly presenting cases of SSNS,
our retention rate is currently close to 90%. The large
majority of PREDNOS investigators are also participat-
ing in the PREDNOS 2 study.
Sample size and power calculation
A total of 300 subjects will be recruited into the study
(150 in each study arm). The primary analysis will be
based on a comparison of the number of URTI-relatedrelapses of nephrotic syndrome in the two study arms
following the first URTI during the 12-month follow-up
period. In children with frequently relapsing SSNS, the
development of an URTI results in relapse in around
50% of instances [7]. In the Abeyagunawardena study,
overall 40 URTIs treated with placebo were followed by
19 (48%) relapses, compared with 7 (18%) relapses in the
prednisolone-treated group. This corresponds to an ab-
solute difference of 30% (a 62.5% proportional reduc-
tion). In the first treatment period, there were 10 (45%)
relapses for 22 placebo-treated children compared with
4 (22%) relapses for 18 prednisolone-treated children
(23% absolute difference, 51% proportional reduction)
[9]. This is a large treatment effect based on a small study
of children on long-term maintenance alternate-day pred-
nisolone therapy in a developing country. Therefore, to
detect a more conservative difference of 17.5% (i.e. 35%
proportional reduction) in URTI-related relapse rate
(i.e. from 50% to 32.5%), with 80% power, 2-sided test and
alpha of 0.05, requires 250 subjects in total (comparison of
two proportions [11]). If allowance is made for between
10% and 20% dropout (e.g. subject withdrawal, lost to
follow-up or subject not having an URTI during the
12-month follow-up period), then this will require recruit-
ment of between 280 and 320 subjects. We therefore
propose to recruit 300 subjects, 150 to each arm. However,
if the treatment effect is more in line with the 50%
reduction observed in the first treatment period of the
Abeyagunawardena study, then this study has sufficient
power (>95%) to detect this difference. To detect a 50%
proportional reduction (i.e. 50% to 25%) with 90% power
and alpha of 0.05, requires 160 subjects, increasing to 200
with allowance for 20% dropout.
Outcome measures
Primary study end point
The primary study end point is URTI-related relapse of
nephrotic syndrome following the first URTI during the 12-
month follow-up period. An URTI-related relapse is defined
as a relapse occurring within 14 days of the onset of URTI.
Secondary end points
The secondary end points are:
 Rate of URTI-related relapse of nephrotic syndrome
(relapses per year)
 Rate of relapse (URTI-related and non URTI-
related) of nephrotic syndrome (relapses per year)
 Cumulative dose of prednisolone (mg/kg and
mg/m2) received over the 12-month study period
 Incidence of serious adverse events
 Incidence of adverse effects due to prednisolone
based on assessment of behaviour using the
Achenbach Child Behaviour Checklist
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immunomodulatory therapy (e.g. addition of
ciclosporin, tacrolimus, cyclophosphamide, etc.)
 Incidence of reduction of background
immunomodulatory therapy (i.e. cessation of
long-term maintenance prednisolone therapy)
 Quality of life using CHU-9D, EQ-5D and PedsQL
 Cost per relapse of nephrotic syndrome
 Cost per quality adjusted life year (QALY) gained
Statistical analysis
The statistical analysis plan describes the planned ana-
lyses for PREDNOS 2 in full detail. A summary of the
main analysis methods are described here. The primary
end point is URTI-related relapse of nephrotic syndrome
following the first URTI during the 12-month follow-up
period. The proportion of subjects that experience an
URTI-related relapse will be calculated for the two study
treatment arms, and compared using a chi-squared test.
Treatment effects will be expressed as relative risks with
95% confidence intervals. This was chosen as the pri-
mary end point as it is hypothesised that giving daily
prednisolone during an URTI will reduce the subsequent
development of disease relapse. If this hypothesis is cor-
rect, then those subjects randomised to the placebo may
experience more disease relapses than those subjects
randomised to the active drug. This would mean that
subjects in the placebo arm are more likely to undergo
intensification of immunomodulatory therapy. Previous
studies excluded these subjects from the study and data
analysis, as escalating therapy may mean that the overall
likelihood of these children relapsing is reduced, which
could introduce bias into the analysis. In PREDNOS 2, a
pragmatic decision has therefore been taken to continue
to follow up these subjects as it is not known whether
these assumptions hold true, and by excluding these
subjects it also introduces bias through the differential
dropout between the two treatment arms. Therefore, all
subjects will be followed up for 12 months to also assess
the relapse rates between the two treatment arms over a
12-month period as secondary end points, however,due
to these potential biases, the primary end point will
focus on the relapse rate following the first URTI. The
secondary end points relating to relapses per year will
assess incidence (relapse) density rates for the two treat-
ment arms and rate differences will be calculated for
both URTI- and non-URTI-related relapse of nephrotic
syndrome over the 12-month follow-up period. An ap-
propriate regression analysis (e.g. Poisson) will be used
to compare relapse rates in the two treatment groups
should there be an imbalance in any important covari-
ates (e.g. URTI rates across the two study arms).
The secondary end points include both continuous
and categorical data items. The dichotomous data(e.g. incidence of escalation of background immunosup-
pressive therapy) will be analysed as per the primary
outcome. Continuous data (e.g. prednisolone dose and
quality of life scores) will be expressed as means and
standard deviations, with differences in means and 95%
confidence intervals. Longitudinal plots of the data over
time will be constructed to give a visual presentation of
the data. The data will be analysed using mixed effect re-
peated measures models with the interventions specified
as independent variables. Baseline data will be included
in the model as a covariate. Analyses will be of all rando-
mised subjects using intention to treat, except for those
who do not have an URTI following randomisation (esti-
mated to be <10%). Exclusion of these subjects will
result in no bias as these dropouts are not related to
the treatment and should by chance be equally distrib-
uted across the two treatment arms (this will be moni-
tored throughout the trial). The only subgroup analyses
planned are an analysis of the background treatment
regimen that the subjects are on at randomisation
(no long-term treatment, on long-term maintenance
prednisolone therapy, on other immunosuppressant
therapy with long-term maintenance prednisolone ther-
apy or on other immunosuppressant therapy without
long-term maintenance prednisolone), an analysis com-
paring those subjects on long-term maintenance pred-
nisolone versus those not on long-term maintenance
prednisolone and an analysis comparing those subjects
on other immunomodulatory therapy versus those not
on other immunomodulatory therapy. There is no evi-
dence to suggest that any difference in treatment effect
will occur and the study is not powered to detect differ-
ences in treatment effect across these subgroups; these
analyses will be considered as hypothesis generating.
Health economic analysis
The economic evaluation will take the form of a cost-
effectiveness analysis based on a primary clinical out-
come of cost per episode of URTI-related relapse of
proteinuria. Utility-based outcomes will also be incorpo-
rated into the model allowing a secondary outcome
to be cost per QALY gained (based on CHU-9D and
EQ-5D values). Four different groups of subjects will be
considered in the model: (i) subjects not on long-term
immunomodulatory therapy, (ii) subjects receiving long-
term maintenance prednisolone therapy, (iii) subjects
receiving long-term maintenance prednisolone therapy
in conjunction with other immunomodulatory therapies
and (iv) subjects receiving long-term immunomodula-
tory therapies without long-term maintenance prednisol-
one therapy. For each of these four groups, the model
will make a direct comparison between two strategies
implemented each time a subject develops an URTI: the
strategy of administering a course of daily prednisolone
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apy (with the use of placebo tablets to maintain blind-
ing). The base case economic evaluation will adopt the
National Health Service (NHS) perspective. NHS costs
will include:
 Treatment costs: medicines, management, adverse-
effects and treatment complications
 Consultation and follow-up costs: routine tests such
as blood tests and urinalysis, number of outpatient
visits, inpatient visits and general practitioner visits
 Longer-term treatment costs (care for long-term
adverse effects)
Resource-use data such as visits to the subject’s gen-
eral practitioner, hospital (as an outpatient or inpatient)
and medicines supplied will be collected using subject-
held record books provided for them. This information
will be collected at the time of study visits. Due to
the economic burden associated with relapse of URTI-
related proteinuria that is placed on patients and their
families, we will also conduct an economic evaluation
that includes private costs such as over-the-counter
medicines and parents’ or guardians’ time off work.
Resource-use data related to these costs will also be col-
lected using patient-held record books. Unit cost data
for both NHS and private costs will be derived from
nationally representative sources such as the British
National Formulary, the National Schedule for Reference
Costs and the Unit Costs of Health and Social Care.
As there are no utility measures validated for use
across the complete age range of the study population
(1 to 18 years), the economic analysis will use a combin-
ation of instruments including the CHU-9D, the EQ-5D
and the PedsQL. This combined approach will allow for
a methodological exploration into the use of utility mea-
sures in this age group whilst ensuring that appropriate
information is collected to facilitate the construction of
QALYs.
To test the robustness of the conclusions to assump-
tions made in the modelling, and to sampling variation
in the data used in the construction of the model, a full
deterministic and probabilistic sensitivity analysis will be
carried out and results will be reported in terms of in-
cremental cost-effectiveness ratios and cost-effectiveness
acceptability curves. Costs and benefits will be dis-
counted at the standard rate (3.5%).
Ethical considerations
Children are considered vulnerable trial subjects; how-
ever, a trial involving children with nephrotic syndrome
is ethically justified as the condition is specific to chil-
dren and the evidence base for treatment used in clinical
practice is inadequate. It is not possible to perform thestudy in adult subjects and extrapolate the results to
children. The active treatment arm will receive a 6-day
course of daily prednisolone at the time of each URTI,
which they develop over the 12-month study period.
Our hypothesis is that this will reduce the risk of subse-
quent relapse and reduce the total amount of prednisol-
one that these subjects are exposed to. There is a risk
that the hypothesis is incorrect and that these subjects
will therefore receive unnecessary additional prednisol-
one treatment with its attendant adverse effects. The
subjects participating in the study will already be receiv-
ing significant annual total doses of prednisolone as a
result of their relapsing disease and the additional pred-
nisolone administered through their participation in
PREDNOS 2 will represent only a relatively small in-
crease in total annual dose. We will carefully monitor
adverse effects of prednisolone in this study, including
the effect on child behaviour.
Reporting of adverse events
Pharmacovigilance reporting will comply with the Medi-
cines for Human Use (Clinical Trials) Regulations 2004
and Amended Regulations 2006. Annual development
safety update reports will be submitted to the main
research ethics committee and the Medicines and
Healthcare Products Regulatory Authority. Within the
PREDNOS 2 trial, prednisolone and the matching pla-
cebo are both defined as investigational medicinal prod-
ucts. Serious adverse events will be reported for the
duration of the 12-month study and for 3 months fol-
lowing treatment with the study drug.
Monitoring
Trial steering committee
The independent members of the trial steering committee
are Dr Megan Thomas (independent expert and chair), Dr
Nigel Coad (independent expert), Mrs Sandra Cope (inde-
pendent consumer representative), Dr Andrew Duncan
(independent expert), Dr Kate Hillman (independent
expert), Dr Zala Ibrahim (independent expert) and Dr
Ly-Mee Yu (independent expert statistician). Additional
non-independent members of the trial steering committee
are Miss Natalie Ives (BCTU statistician) and Professor
Nicholas Webb (chief investigator).
Additional trial steering committee attendees are Miss
Emma Barsoum (BCTU study manager), Mrs Elizabeth
Brettell (BCTU renal trials manager), Dr Martin Christian
(principal investigator), Professor Peter Clayton (external
expert), Mrs Wendy Cook (consumer representative), Dr
Richard Coward (investigator), Dr Carol Cummins (exter-
nal expert), Dr Emma Frew (health economist), Mr Terry
Hughes (BCTU renal data manager), Miss Charmaine
Meek (BCTU renal data manager), Dr Richard Trompeter
(external expert) and Miss Rebecca Wooley (statistician).
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The members of the independent data monitoring com-
mittee are Professor Philip Kalra (chair), Professor Saul
Faust and Dr Andrea Marshall.
Regulatory aspects
PREDNOS 2 is sponsored by the Central Manchester
University Hospitals NHS Foundation Trust and the
University of Birmingham (RG_12-188). The Medi-
cines and Healthcare Products Regulatory Authority
clinical trial authorisation reference is 21761/0281/
001-0001. The EudraCT number is 2012-003476-39.
The active study drug and placebo are manufactured
in accordance with current Good Manufacturing
Process regulations. The study will be conducted in
compliance with the Research Governance Frame-
work for Health and Social Care, the Medicine for
Human Use (Clinical Trials) Regulation 2004 and
Good Clinical Practice.
Ethical committee approval
Ethical approval for PREDNOS 2 was granted by the
National Research Ethics Service Committee North
West – Greater Manchester Central (12/NW/0766) on 4
December 2012.
Discussion
Potential impact
There is substantial disease- and treatment-related mor-
bidity associated with disease relapses in SSNS. PRE-
DNOS 2 will be the largest ever study to investigate
whether the administration of a 6-day course of daily
prednisolone therapy given at the time of onset of URTI
prevents the subsequent development of a disease re-
lapse. Furthermore, the study will include children with
SSNS receiving a wide range of long-term maintenance
immunomodulatory therapies, in contrast to previous
studies, which focused upon children receiving long-
term maintenance prednisolone and levamisole only. If
it is possible to reduce the disease relapse rate effectively
and safely using the intervention being tested in PRE-
DNOS 2, this will reduce relapse-associated morbidity
and the cost associated with drug treatment, possible
hospital admission and parental absence from employ-
ment. PREDNOS 2 will be the first study in patients
with relapsing SSNS that will incorporate a formal
health economic analysis and investigate quality of life.
The proposed intervention (6 days of daily prednisol-
one) is simple to administer and would be easy to intro-
duce into routine clinical practice were the results of
this study to recommend its use. The parents and guard-
ians of children with SSNS are used to introducing
changes to prednisolone treatment based upon theresults of urinalysis performed in the home, and main-
tain supplies of the drug in the home for use at such
times.
The study also proposes to use additional analyses to
examine whether genetic background and/or deleterious
gene variants result in SSNS, beyond genes already
known to be associated with certain types of childhood
nephrotic syndrome. It is anticipated that these may well
provide valuable information about disease pathogenesis,
as well as potentially predict disease progression, either
through contributing to our existing knowledge on
podocyte dysfunction or by indicating which patients
may respond better to medication.
Dissemination
The study results will be published in accordance with
the CONSORT statement and SPIRIT guidelines [12,13].
Our findings will be submitted to major international
paediatric nephrology and general paediatric meetings,
and submitted for publication in a high impact factor
journal, with open access. The results will also be com-
municated in plain English to study participants and
their families.
Trial status
As of 2 April 2014 a total of 80 children have been re-
cruited into the study.
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